Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of immune checkpoint inhibitors (pembrolizumab, nivolumab and atezolizumab) in combination with chemotherapy and targeted treatment in patients with advanced/refractory cancer

Next Previous
Trial Profile

Safety and efficacy of immune checkpoint inhibitors (pembrolizumab, nivolumab and atezolizumab) in combination with chemotherapy and targeted treatment in patients with advanced/refractory cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cetuximab (Primary) ; Erlotinib (Primary) ; Everolimus (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Antineoplastics
  • Indications Cancer; Cervical cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Glioblastoma; Hodgkin's disease; Lung cancer; Malignant melanoma; Pancreatic cancer; Thymoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 16 Jun 2020 New trial record
  • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top